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Abstract 
Purpose: Tumor growth and progression requires multiple steps and genetic alterations. 
The molecular events that occur as tumors increase in size are unknown. Patients with von 
Hippel-Lindau (VHL) provide a unique opportunity to study molecular alterations during 
tumor growth as these patients develop multiple bilateral renal tumors. To better charac-
terize biologic events associated with tumor growth, we evaluated the alterations in gene 
expression in large versus small renal tumors removed from the same kidney of the same 
individuals. 
Experimental  Design:  We reviewed pathology reports from patients who underwent 
partial nephrectomies at the National Cancer Institute for multiple tumors. We identified 11 
patients who fulfilled the following inclusion criteria: 1) The patient must have had a surgical 
resection of more than one solid tumor from the same kidney during the same operation; 2) 
Among the solid tumors at least one must have been greater than 3 cm in the largest di-
mension and at least one less than 2 cm; 3) the nuclear Furhman grade for both larger and 
smaller solid tumors was identical; 4) a portion of each tumor was procured and snap frozen 
after surgical removal; 5) Hematoxylin and eosin staining of the frozen sample confirmed clear 
cell carcinoma to be present in at least 80% of the section.  
Affymetrix platform and protocol for gene expression arrays were used. RNA from the 
frozen large and small tumor samples was extracted using Trizol-Chlorophorm method. The 
RNA was then reverse transcribed, labeled, fragmented, and hybridized on to an Affymetrix 
U133 Plus 2.0 array that contains 54,000 probe sets representing 24,568 genes. Analysis in-
cluded unsupervised clustering and chromosomal analysis. The paired t-test was performed to 
compare gene expression levels in small and large tumors. P<0.01 was considered statistically 
significant. 
Results: Gene expression profiles were assessed for 22 tumors (11 patients). Upon unsu-
pervised clustering the pairs with larger tumor volume difference clustered separately from 
pairs with smaller volume difference. Chromosomal analysis revealed few consistent changes 
other than reduced expression of chromosome 3p25 among all tumors. Paired t-test showed 
860 differentially expressed genes in the T1b vs T1a group, a number far greater than ex-
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pected due to chance alone. When analyzed by gene function, most differences were ob-
served in genes involved in DNA replication and in cytokine signaling.  
Conclusions: This study demonstrates that as tumors increase in size there is an increasing 
difference in gene expression. Unsupervised clustering analysis confirms that as the volume 
difference increases there are a distinct set of genes that are regulated either as a response to 
a tumor’s growth or as an early event that causes the tumor to grow. While we did not 
observe chromosomal instability, we did note differences in expression of individual tran-
scripts as tumors grew larger. 
Key words: Renal cell carcinoma, tumor, size, microarray, kidney 
Introduction and Objectives 
During  the  last  two  decades,  the  molecular 
events  that  lead  to  the  formation  of  renal  cell 
carcinoma have been elucidated, particularly for the 
clear cell type (ccRCC). Most clear cell renal tumors 
form  as  the  result  of  dysregulation  of  the  von 
Hippel-Lindau  tumor  (VHL)  suppressor  gene  with 
loss-of-function  somatic  mutations  and  epigenetic 
silencing that may be found in up to 90% of sporadic 
ccRCC (1). While the inciting genetic events that lead 
to the formation of ccRCC have been worked out in 
great detail, the events that give primary tumors the 
ability  to  grow  and  potentially  gain  aggressiveness 
remain poorly understood.  
There is a strong relationship between the size of 
the  primary  tumor  and  likelyhood  of  metastasis. 
Frank et al demonstrated that estimated cancer spe-
cific  survival  rates  for  tumors  >7cm  were  15-25% 
higher than for tumors that were less than <7cm fol-
lowing nephrectomy (2). In a separate study from the 
NCI of a cohort of patients with inherited germline 
mutations of the VHL gene, there have been no cases 
of metastasis of tumors less than 3 cm (3). To explore 
the genetic events involved in the development and 
progression  of  ccRCC  as  tumors  grow  larger,  we 
surveyed  the  global  gene  expression  profiles  of 
tumors of different sizes in patients with confirmed 
germline  VHL  gene  mutations.  By  using  tumors  of 
different  sizes  removed  from  the  same  patient,  we 
aimed  to  study  the  differences  in  genetic  profiles 
associated with increase in tumor size.  
Materials/Methods 
Patient selection 
Pathology reports from patients who underwent 
partial nephrectomies for multiple renal tumors at the 
National Cancer Institute were reviewed. Eleven pa-
tients fulfilled the following inclusion criteria: 1) The 
patient must have had a surgical resection of more 
than one solid tumor from the same kidney during the 
same operation; 2) Among the solid tumors at least 
one must have been greater than 3 cm in the largest 
dimension while the other removed solid tumor was 
less than 2 cm; 3) the nuclear Furhman grade for both 
larger  and  smaller  solid  tumors  was  identical;  4)  a 
portion of each tumor was procured and snap frozen 
after  surgical  removal;  5)  Hematoxylin  and  eosin 
staining of the frozen sample confirmed clear cell car-
cinoma to be present in at least 80% of the section. 
Original  tumor  volumes  were  calculated  using  the 
formula  for  an  ellipsoid  (4/3πr3).  All  patients  had 
confirmed  mutations  in  the  VHL  tumor  suppressor 
gene. All patients were enrolled in an IRB approved 
NIH intramural research protocol. 
A summary of the tumor sizes for the eleven pa-
tients included in this study can be seen in Table 1. 
Four pairs have at least 1 tumor >4cm (used to com-
pare T1a vs T1b), and seven pairs have two tumors 
<4cm (used to compare T1a vs T1a). 
An example of the multifocal renal tumors in a 
patient with VHL disease can be seen in the bivalved 
nephrectomy  specimen  in  Figure  1  demonstrating 
multiple  tumors  of  different  sizes  throughout  the 
kidney.  
RNA Isolation 
Fifteen  20μm  thick  frozen  sections  from  each 
tissue sample were homogenized in TRIZOL reagent 
(Invitrogen  Life  Techonolgies,  Carlsbad,  CA  USA). 
Total RNA was extracted using a standard chloroform 
protocol  followed  by  purification  with  the  Qiagen 
RNeasy Mini Kit (QIAGEN Inc, Valencia, CA USA). 
RNA  integrity  was  evaluated  by  using  RNA  6000 
Nano LabChips on an Agilent 2100 Bioanalyzer (Ag-
ilent Technologies, Foster City, CA USA). RNA purity 
was assessed by the ratio of spectrophotometric ab-
sorbance  at  260  and  280  nm  (A260/280nm)  using 
NanoDrop ND-1000 (NanoDrop Inc, Wilmington, DE 
USA). All chips were prepared according to the man-
ufacturer’s instructions. Total RNA degradation was 
evaluated  by  reviewing  the  electropherograms  and 
the RNA integrity number (RIN): only samples with 
preserved 18S and 28S peaks and RIN values greater 
than 7 were selected for gene expression analysis.  Journal of Cancer 2011, 2 
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Table 1. Tumor sizes for the patients 
  Size  Tumor size (cm)  Size Difference (cm)  Tumor volume (cc3)  Volume Difference (cc3) 
Patient 1  large  6  4.7  84.8  84.0 
  small  1.3    0.8   
Patient 2  large  5.5  3.7  25.9  24.5 
  small  1.8    1.4   
Patient 3  large  5.2  4  34.3  31.9 
  small  1.2    2.4   
Patient 4  large  4.5  2.5  24.7  22.0 
  small  2    2.7   
Patient 5  large  3.5  1.7  11.9  11.4 
  small  1.8    0.5   
Patient 6  large  3.5  2  9.2  8.9 
  small  1.5    0.3   
Patient 7  large  3.4  2.1  15.9  15.3 
  small  1.3    0.6   
Patient 8  large  3.1  1.1  11.8  10.3 
  small  2    1.5   
Patient 9  large  3  1  4.7  2.3 
  small  2    2.4   
Patient 10  large  3  1.6  7.9  6.8 
  small  1.4    1.1   
Patient 11  large  3  1.8  14.1  13.8 
  small  1.2    0.3   
 
 
 
Figure 1. Multiple renal tumors with a single renal unit: bivalved nephrectomy specimen from a patient with a germline 
mutation in the VHL gene. 
 Journal of Cancer 2011, 2 
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Figure 2. Hierarchical clustering of tumor pairs based on differences in size. The volume difference between larger and 
smaller tumor is listed in parenthesis for each patient. 
 
Microarray hybridization and Image Acquisition 
Messenger  RNA  expression  levels  were  meas-
ured  using  the  GeneChip®  HG-U133  plus  2.0  plat-
form  following  the  manufacturer’s  protocol  (Affy-
metrix  Inc,  Santa  Clara,  CA  USA).  Briefly,  dou-
ble-stranded  cDNA  was  synthesized  from  11µg  of 
total RNA from each tumor sample using GeneChip 
Two-Cycle  cDNA  Target  Synthesis  Kit  (Affymetrix 
Inc, Santa Clara, CA USA). After one round of ampli-
fications, in vitro transcription was performed using 
IVT  Labeling  Kit  (Affymetrix  Inc,  Santa  Clara,  CA 
USA) to synthesize biotin-labeled cRNA. An aliquot 
of  15ug  labeled  cRNA  was  fragmented  and  subse-
quently hybridized for 16 hours at 45C in a hybridi-
zation  oven  to  a  HG-U133  plus  2.0  olgionucleotide 
array.  Arrays  were  washed  and  scanned  with  an 
Affymetrix GeneChip 3000 Scanner. 
Statistical Analysis 
Raw data (.CEL) files were imported into BRB 
array tools (4). The data were normalized using the 
RMA  algorithm  (5).  Unsupervised  clustering  was 
performed  using  hierarchical  clustering 
(1-correlation)  based  on  the  differences  in  size  be-
tween  large  and  small  tumors.  The  data  were  then 
separated into two groups for supervised analysis: the 
first consisted of pairs of tumors that were both T1a 
(<4cm), and the second group had one T1a tumor and 
one T1b (between 4 and 7 cm) to evaluate the accepted 
size cut offs of AJCC staging. Differences in gene ex-
pression  were  analyzed  using  a  paired  t-test  with 
random  variance  model  set  at  1000  permutations. 
Significant P-value was set at 0.01. BRB array tools 
was  used  to  analyze  which  categories  are 
over-represented  relative  to  the  prevalence  of  Gene 
Ontology categories on the array (4). 
Data were then imported into the R environment 
for  further analysis (www.r-project.org). Chromoso-
mal  abnormalities  were  assessed  with  a  technique 
known as comparative genomic microarray analysis. 
This method has been shown to have good correlation 
with  more  traditional  CGH  techniques  (6).  For  a 
common reference pool, a pool of normal renal pa-
renchyma  from  the  gene  expression  omnibus  data-
base (http://www.ncbi.nlm.nih.gov/geo/) was used 
(GSE7392). 
Results 
 The results of unsupervised clustering based on 
the volume difference of the pairs can be seen in Fig-
ure 2. With one exception, the pairs with larger dif-
ferences  in  volume  clustered  separately  from  pairs Journal of Cancer 2011, 2 
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with smaller differences.  
A schematic of the results of the paired t-test are 
observed in figure 3. The Affymetrix HGU133 plus 2.0 
has 54,675 probe sets. The threshold for significance 
was set at 0.01. Thus, we would expect approximately 
550 false positives. In the paired analysis where both 
tumors were less than 4cm, there were 458 genes were 
differentially expressed, less than would be expected 
by  chance.  When  tumors  greater  than  4cm  were 
compared to tumors less than 4cm in the same patient, 
there were 890 differentially expressed genes identi-
fied, which is greater than the expected false positives. 
When we examined the gene ontology of the signifi-
cant gene changes, we found that transcripts involved 
in  cytokine  production  and  DNA  synthesis  to  be 
over-represented (Table 2). 
The first part of the cGMA chromosomal analy-
sis was an examination of the expression pattern for 
chromosome 3. Since all the patients had a confirmed 
VHL  mutation,  as  expected  the  level  of  expression 
was  decreased  in  chromosome  3p25  in  all  samples 
when compared to normal renal parenchyma (Figure 
4). Interestingly, there is was also a decrease in gene 
expression near chromosome 3p21. Full chromosomal 
analysis revealed that the expression profiles within 
each pair appeared similar. No consistent differences 
in  expression  on  chromosomal  level  between  large 
and small tumors were observed. (Figure 5).  
Table 2. Gene ontology 
GO ID  GO Term  Observed/ 
Expected 
GO:0032602  chemokine production  8.08  
GO:0042364  water-soluble vitamin biosynthetic 
process 
6.79  
GO:0051187  cofactor catabolic process  6.57  
GO:0034381  lipoprotein particle clearance  6.47  
GO:0009110  vitamin biosynthetic process  5.5  
GO:0006306  DNA methylation  5.39  
GO:0006305  DNA alkylation  5.39  
GO:0007031  peroxisome organization  4.85  
GO:0031047  gene silencing by RNA  4.53  
GO:0006304  DNA modification  4.04  
GO:0030336  negative regulation of cell migration  3.99  
GO:0001935  endothelial cell proliferation  3.93  
GO:0016458  gene silencing  3.85  
GO:0043542  endothelial cell migration  3.83  
GO:0009062  fatty acid catabolic process  3.83  
GO:0045765  regulation of angiogenesis  3.7  
GO:0051271  negative regulation of cell motion  3.64  
GO:0043414  biopolymer methylation  3.45  
GO:0045762  positive regulation of adenylate 
cyclase activity 
3.38  
GO:0019362  pyridine nucleotide metabolic process  3.31  
GO:0022618  ribonucleoprotein complex assembly  3.17  
GO:0006733  oxidoreduction coenzyme metabolic 
process 
3.17  
GO:0031281  positive regulation of cyclase activity  3.16  
GO:0051349  positive regulation of lyase activity  3.1  
  
 
 
 
Figure 3. Column graph of the observed and expected gene expression changes based on chance alone. In the T1a vs T1b 
group, there are more changes than would be expected by chance.   Journal of Cancer 2011, 2 
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Figure 4. Comparative genome microarray analysis of chromosome 3. Note that each tumor sample has reduced ex-
pression of the short arm of chromosome 3, the site of the VHL gene 
 
 
Figure 5. Comparative genomic microarray analysis – global chromosomal heat map. No consistent differences in ex-
pression on chromosomal level between large and small tumors were observed. Note that the changes between individuals 
are greater than changes between tumors of different size in a given individual.  Journal of Cancer 2011, 2 
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Discussion 
Renal  tumors  in  patients  with  von  Hippel 
Lindau syndrome result from biallelic inactivation of 
the VHL gene located on chromosome 3p25 with one 
allele  inactivated  via  a  germline  mutation  and  the 
second due to a random somatic event (7). The protein 
product of the VHL gene (pVHL) is a key component 
of an ubiquitin ligase complex that marks the alpha 
subunit of hypoxia inducible factor (HIF) for degra-
dation (8). The VHL protein serves a critical role in 
prevention  of  dysregulated  HIF-alpha  levels  (9). 
Downregulation of HIF-a by pVHL has been shown to 
be both necessary and sufficient for renal tumor sup-
pression. In the absence of pVHL patients are prone to 
form  tumors  of  the  retina,  CNS,  kidneys,  pancreas, 
and epididymis (10).  
Among  the  most  severe  manifestations  of  the 
VHL  syndrome  are  the  renal  manifestations.  These 
patients are at risk for forming multiple bilateral clear 
cell renal cell carcinomas – as many as 70 clinically 
lesions in one kidney have been documented to be 
removed  (11).  Despite  multiple  foci  of  disease  that 
cumulatively represent substantial tumor burden, the 
renal tumors in patients with VHL do not attain the 
ability to metastasize until the largest tumor reaches 
3cm (3). Similar to VHL tumors, size of sporadic renal 
masses is also one of the most important prognostic 
indicators in sporadic RCC. Frank et al estimated 5 
year survival rates to be 97% for patients with T1a 
(<4cm) tumors, 87% for patients with T1b tumors (4-7 
cm), and 71 % for patients with T2 disease (>7cm) (2). 
While  the  relationship  between  size  and  metastatic 
potential is well-established, molecular changes that 
are associated with tumor growth are poorly charac-
terized. 
In the present study we investigated the changes 
in  gene  expression  profiles  that  occur  with  tumor 
growth by performing microarray analysis on small 
and large tumors from the same patient. Interestingly, 
unsupervised clustering revealed that the tumor pairs 
with  larger  volume  differences  clustered  separately 
from  tumor  pairs  with  smaller  volume  differences. 
This suggests that the global transcriptome of larger 
tumors are more biologically dissimilar from smaller 
tumors within the same patient. Such observation is of 
potential clinical relevance as these tumors were not 
only  resected  from  the  same  patient  and  the  same 
kidney,  they  had  the  same  germline  mutation,  and 
were  exposed  to  the  same  environmental  and  host 
factors throughout their development. Therefore, the 
differences  observed  may  be  representative  of  bio-
logically  significant  processes  because  the  only  dif-
ference between the tumors was their size.  
 We were also able to investigate the nature of 
the genetic changes on a chromosomal level between 
large and small tumors. CGMA was used to examine 
gene expression changes between tumor samples and 
a pool of normal renal parenchyma samples. Analysis 
of  the  gene  expression  from  each  chromosome  re-
vealed only one area that had decreased expression 
across all samples: 3p - the location of the VHL gene. 
These findings are also useful as confirmatory results 
of  our  analysis,  demonstrating  global  loss  of  gene 
expression on the 3p, consistent with the VHL sam-
ples studied.  
In addition to demonstration of 3p loss as a con-
firmation of our analyses, the study of cytogenetics 
may  be  particularly  relevant  in  patients  with  VHL. 
Indeed, inactivation of  pVHL  was found to lead to 
defects  in  spindle  orientation  thus  provoking  chro-
mosomal instability (12). Consistent with this theory, 
multiple  chromosomal  abnormalities  have  been  re-
ported in the literature for patients with both heredi-
tary and sporadic ccRCC (13, 14). For example, Phil-
lips et al performed cytogenetic studies on cell lines 
derived from vHL patients with multifocal RCC and 
found that higher stage tumors were associated with a 
greater degree of aneupolidy (14).  
Notably, not all studies demonstrated genomic 
instability  in  RCC.  A  study  of  the  sporadic  ccRCC 
population failed to show an association between the 
degree of genomic instability and the clinical stage of 
renal  tumors  (13).  Interestingly,  another  large  scale 
study of 432 clear cell renal tumors supported the loss 
of chromosome 3p as a common event in the devel-
opment of ccrCC (60%), but the prevalence of other 
chromosomal aberrations were much lower (14% for 
loss of chromosome 4p to 33% for gain of chromo-
some 5q). In that study, loss of chromosome 9 was the 
only independent predictor associated with survival 
(15). The lack of chromosomal changes between larger 
and smaller tumors in our study is inconsistent with 
the  concept  that  chromosomal  instability  occurs  in 
larger tumors. However, it should be noted that all 
our samples are derived from T1 tumors, which are 
associated with a very good prognosis. In contrast, the 
tumors  studied  by  Phillips  et  al  included  a  wider 
spectrum  of  disease,  including  tumors  that  had 
achieved  the  ability  to  metastasize  (14).  Therefore, 
chromosomal instability may be a late, rather than an 
early event, in tumor progression. 
While  consistent  cytogenetic  changes  between 
large and  small  tumors  were  not  observed,  we  did 
note significant changes in the expression of individ-
ual genes. For this analysis, our sample was split into 
two groups: groups where the larger tumor was less 
than 4 cm (T1a) and groups where the larger tumor Journal of Cancer 2011, 2 
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was greater than 4cm (T1b). As Figure 3 demonstrates, 
the number of statistically significant genetic changes 
between large and small tumors was no greater than 
would  be  expected  by  random  chance  when  both 
tumors were T1a. This finding further supports the 
strategy used at the urologic oncology branch at the 
NCI, when small tumors are surveilled until the larg-
est tumor reaches 3 cm (Duffey at al). However, once 
the largest tumor reached T1b size (greater than 4cm), 
the number of statistically significant genetic changes 
between  larger  and  smaller  tumors  becomes  much 
greater than would be expected by random chance. 
This suggests that even in the absence of large cyto-
genetic changes, there are significant changes in gene 
expression  as  tumors  grow  larger.  When  Gene  On-
tology analysis was performed, it demonstrated that 
there  was  an  over-representation  of  transcripts  in-
volved in DNA replication and in cytokine signaling, 
particularly IL-6. This may be clinically elevant, espe-
cially  since  cytokine  therapy  is  one  of  the  durable 
treatments used for advanced ccRCC. 
This study represents one of the first attempts to 
perform  microarrays  on  tumors  derived  from  the 
same  patient.  Gieseg  studied  the  gene  expression 
profiles of smaller (200mg) and larger tumors (1000 
mm) in subcutaneously grown tumors from cell lines, 
and found no difference in gene expression between 
large and small tumors (16). This is not unexpected as 
a cell line represents a clonal population of cells that 
has been selected for high proliferative ability. Perou 
et  al  examined  breast  cancer  samples  derived  from 
primary tumor and lymph nodes in the same patient, 
and found that gene expression patterns in two tumor 
samples  from  the  same  individual  were  almost  al-
ways more similar to each other than either was to 
any other sample (17). Similarly, Chen et al examined 
multiple  tumors  from  patients  with  HCC  (18).  The 
investigators noted that the most important factor in 
clustering was the individual of origin, not the size of 
the  tumor.  They  found  genetic  differences  between 
clonally related tumors. Consistent with our findings, 
the differences were particularly evident in one pa-
tient  with  a  large  tumor  (8cm),  who  had  different 
chromosomal  abnormalities  than  smaller  tumors  in 
the same patient (1cm and 2cm) (18).  
The results of prior studies on tumors from the 
same  patient  corroborate  our  data.  It  appears  that 
each  individual  has  a  very  distinct  pattern  of  tran-
scribed genes when surveyed by gene expression mi-
croarray. Tumors have genetic aberrations, but con-
tinue to have a transcriptome that is more similar to 
its parental pattern than to another individual’s tran-
scriptome. Our data provide evidence of differences 
in gene expression between larger and small renal cell 
carcinoma  tumors,  although  the  number  of  differ-
ences may small in number in T1 renal tumors. It may 
not be until renal tumors are even larger that chro-
mosome instability would be detectable. 
Of note, our size criteria were chosen to reflect a 
clinically useful landmark. Tumors less than 4cm are 
also known as small renal masses. As the use of CT 
scans  increases,  the  incidence  of  these  small  renal 
masses is rising, creating a new debate about the uti-
lization of active surveillance in select patients (19). 
We found that there may be a biologic basis for this 
practice by demonstrating few genetic differences in 
T1a tumors. Consistent with our findings, recent work 
from MSKCC studying metastatic events of sporadic 
RCC, found the metastatic rate negligible in patients 
with renal masses less than 3cm (20). However, as the 
size of the tumors increases beyond 4 cm, there are 
ongoing  changes  in  the  transcriptome,  possibly  re-
flecting  the potential  change in  biologic aggressive-
ness. 
The present study has a few limitations. First, the 
samples analyzed were archived, and there is a pos-
sibility that some of the observed changes may be due 
to  a  length  of  storage  and  procurement  conditions. 
Second, although all patients had VHL, the different 
germline mutations or the second hits of the normal 
allele may have also be a variable, determining the 
expression profile of the tumors studied. Third, the 
sample  size  is  small  (although  it  includes  patients 
treated during a period of 5 years at the NCI). Finally, 
we recognize that the transcriptome analysis do not 
always translate into proteome and biologic signifi-
cance. Despite these limitations, this is the first study 
in RCC that compares the expression levels of large 
and small tumors obtained from the same individual 
in the same setting. Additionally, his study may pro-
vide new biologic rationale for active surveillance of 
small renal masses, practiced for years at the National 
Cancer Institute. 
Conclusion 
Through analysis of genetic expression profiles 
between larger and smaller tumors in the same pa-
tient, we found that larger tumor volume differences 
progressively increased global transcriptome changes. 
Although few changes in gene expression were ap-
preciated on a chromosomal level, on the level on the 
individual  transcripts,  there  were  an  increasing 
number of changes between large and small tumors, 
especially  when  the  larger  tumor  was  greater  than 
4cm (T1b). This may provide a genetic rational behind 
active surveillance of small renal masses in select pa-
tients and further support practice of active surveil-
lance at the Urologic Oncology Branch at the NCI. Journal of Cancer 2011, 2 
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